Rare Diseases Clinical Research Consortia (RDCRC) for the RDCR Network
Rare Diseases Clinical Research Consortia (RDCRC) for the RDCR Network
批准号:
7932561
负责人:
MARK L. BATSHAW
金额:
$30.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-09-29
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Urea cycle disorders (UCD) are a group of 8 rare but devastating inborn errors of metabolism that carry a
high mortality and morbidity from the newborn period through adulthood. UCD include deficiencies in any of
the six enzymes and two membrane transporters involved in urea biosynthesis: N-acetylglutamate synthase
(NAGS); Carbamyl phosphate synthase I (CPSI) deficiency; Ornithine transcarbamylase deficiency (OTCD);
Argininosuccinate synthase (AS) deficiency (Citrullinemia); Argininosuccinate lyase (AL) deficiency
(Argininosuccinic aciduria); Arginase (ARG) deficiency (Argininemia); Hyperornithinemia, hyperammonemia,
homocitrullinuria (HHH) syndrome; and Citrullinemia type II. During the previous grant period we have
created the Urea Cycle Disorders Consortium (UCDC) within the Rare Diseases Clinical Research Network
(RDCRN) and have launched successfully four research projects aimed at understanding the natural history
of UCD and developing new tools for treatment. Currently the UCDC consists of 8 U.S. sites with an
interdisciplinary team of over 40 investigators and staff. The consortium works closely with the National
Urea Cycle Disorders Foundation, the patient advocacy organization for urea cycle disorders and has
collaboration with industry to develop innovative therapies for these disorders. We propose in this
application 3 full clinical research projects and a pilot project. In the clinical projects we will: 1) Continue our
longitudinal study that investigates the natural history, morbidity, mortality and biomarkers in children and
adults with UCD; 2) Perform a Phase ll/lll trial of N-carbamylglutamate to assess its efficacy in normalizing
ureagenesis in patients with carbamyl phosphate 1 and ornithine transcarbamylase deficiencies; and 3)
Assess neural mechanisms of injury in OTCD using structural MRI, functional MRI, and magnetic resonance
spectroscopy. In the proposed initial pilot project we will study substrate availability for nitric oxide synthesis
and associated pathogenesis in arginase and argininosuccinate lyase deficiencies. In addition to the
research studies, we will expand and enhance our website for educational and research resources and
continue to provide training and career development opportunities through the UCDC educational programs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rare Disease Clinical Research Training Program
-
批准号:10489961
-
项目类别:
-
资助金额:$16.15万
-
财政年份:2022
-
负责人:MARK L. BATSHAW
-
依托单位:
Career Development
-
批准号:8858730
-
项目类别:
-
资助金额:$8.6万
-
财政年份:2014
-
负责人:MARK L. BATSHAW
-
依托单位:
Longitudinal Study of Urea Cycle Disorders
-
批准号:8858722
-
项目类别:
-
资助金额:$74.17万
-
财政年份:2014
-
负责人:MARK L. BATSHAW
-
依托单位:
Biomarkers of Neurological Injury and Recovery in Urea Cycle Disorders
-
批准号:8858723
-
项目类别:
-
资助金额:$10.01万
-
财政年份:2014
-
负责人:MARK L. BATSHAW
-
依托单位:
Overall Adminstration of Rare Diseases Clinical Research Consortia (RDCRC)
-
批准号:8858731
-
项目类别:
-
资助金额:$17.22万
-
财政年份:2014
-
负责人:MARK L. BATSHAW
-
依托单位:
Pilot/Demonstration Clinical Research Projects Program
-
批准号:8858726
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2014
-
负责人:MARK L. BATSHAW
-
依托单位:
Nitric Oxide Supplementation as a Therapeutic Intervention in Argininosuccinate Lyase Deficiency
-
批准号:8858725
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2014
-
负责人:MARK L. BATSHAW
-
依托单位:
Rare Diseases Clinical Research Consorita (RDCRC) for the RDCR Network
-
批准号:8536435
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2012
-
负责人:MARK L. BATSHAW
-
依托单位:
Investigation of Brain Nitrogen Metabolism in Partial Ornithine Trascarbamylase
-
批准号:8325108
-
项目类别:
-
资助金额:$8.29万
-
财政年份:2011
-
负责人:MARK L. BATSHAW
-
依托单位:
General Clinical Research Center
-
批准号:7919756
-
项目类别:
-
资助金额:$19.67万
-
财政年份:2009
-
负责人:MARK L. BATSHAW
-
依托单位:
Gene Therapy for Urea Cycle Disorders
-
批准号:8474803
-
项目类别:
-
资助金额:$106.81万
-
财政年份:2008
-
负责人:MARK L. BATSHAW
-
依托单位:
Gene Therapy for Urea Cycle Disorders
-
批准号:8271464
-
项目类别:
-
资助金额:$119.6万
-
财政年份:2008
-
负责人:MARK L. BATSHAW
-
依托单位:
Gene Therapy for Urea Cycle Disorders
-
批准号:8846625
-
项目类别:
-
资助金额:$105.81万
-
财政年份:2008
-
负责人:MARK L. BATSHAW
-
依托单位:
Gene Therapy for Urea Cycle Disorders
-
批准号:8652988
-
项目类别:
-
资助金额:$107.09万
-
财政年份:2008
-
负责人:MARK L. BATSHAW
-
依托单位:
RARE DISEASES CRC: UREA CYCLE DISORDERS
-
批准号:7724756
-
项目类别:
-
资助金额:$91.5万
-
财政年份:2007
-
负责人:MARK L. BATSHAW
-
依托单位:
RARE DISEASES CRC: UREA CYCLE DISORDERS
-
批准号:7622818
-
项目类别:
-
资助金额:$117.21万
-
财政年份:2007
-
负责人:MARK L. BATSHAW
-
依托单位:
RARE DISEASES CRC: UREA CYCLE DISORDERS
-
批准号:7380788
-
项目类别:
-
资助金额:$120.21万
-
财政年份:2006
-
负责人:MARK L. BATSHAW
-
依托单位:
RARE DISEASES CRC: UREA CYCLE DISORDERS
-
批准号:7167049
-
项目类别:
-
资助金额:$125.0万
-
财政年份:2005
-
负责人:MARK L. BATSHAW
-
依托单位:
General Clinical Research Center
-
批准号:7195079
-
项目类别:
-
资助金额:$216.83万
-
财政年份:2005
-
负责人:MARK L. BATSHAW
-
依托单位:
PBTC 007V30 -A PHASE 1/11TRIAL OF ZD1839 (IRESSATM)
-
批准号:7199722
-
项目类别:
-
资助金额:$0.29万
-
财政年份:2005
-
负责人:MARK L. BATSHAW
-
依托单位:
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
-
批准号:31171277
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:Christine Nardini
-
依托单位: